GlassScriptPhysician profile
Louis J Avvento
NPI 1417999533
$1,144.12
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.49 · 2020: $144 · 2021: $93.11 · 2022: $299 · 2023: $445 · 2024: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.79 |
| Education | $122.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $157.21 | 2022 | |
| Kite Pharma, INC. | $132.99 | 2020-2021 | |
| Genmab U.S., INC. | $125.00 | 2023 | Epkinly |
| Mirati Therapeutics, INC. | $125.00 | 2023 | Krazati |
| Astrazeneca Pharmaceuticals LP | $123.65 | 2024 | Tagrisso |
| Genzyme Corporation | $117.53 | 2022 | |
| Janssen Biotech, INC. | $92.14 | 2023 | Carvykti, Darzalex, Tecvayli |
| Sobi, INC | $82.99 | 2023 | |
| Merck Sharp & Dohme LLC | $55.03 | 2019-2023 | Keytruda |
| Cti Biopharma Corp. | $24.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.51 | 2020 | |
| Dendreon Pharmaceuticals LLC | $24.37 | 2020 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Secura Bio, INC. | $15.90 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Avvento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.